first edition (1980) of the Orange Book - FDA Law Blog

More documents

Recommendations

Info

AEROSOLCAPSULECAPSULE, CONTROLLED RELEASECONCENTRATECREAMDRESSINGDROPSELI XIREMULSIONENEMAFILM, CONTROLLED RELEASEGASGELGRANULEINJECTABLEINSERT, CONTROLLED RELEASEINTRAUTERINE DEVICEJELLYLIQUIDLOTIONTABLE IDOSAGE FORMSOINTMENTPASTEPELLETPOWDERPOWDER FOR RECONSTITUTIONSHAMPOOSOAPSOLUTIONSPONGESPRAYSUPPOSITORYSUSPENSIONSWABSYRUPTABLETTABLET, CHEWABLETABLET, CONTROLLED RELEASETABLET, EFFERVESCENTTABLET, ENTERIC COATEDTAMPONTAPEBUCCALIMPLANTATIONINHALATIONINJECTIONINTRATRACHEALINTRAUTERINEIRRIGATIONNASALOPHTHALMICTABLE I IROUTES OF ADMINISTRATIONORALOTICPERCUTANEOUSRECTALSUBLINGUALTOPICALURETERALURETHRALVAGINALTABLE I IIABBREVIATIONSAMPAMPULEMEQMI LLI EQUI VALENTAMPICIL AMPICILLIN MG MI LLIGRAMBOT BOTTLE ML MI LLI LITERCI CURl E N/ A NOT APPLICABLEEQ EQUIVALENT TO SQ CM SQUARE CENTIMETERFL OZ FLUID OUNCE UCI MICROCURIEGM GRAM UGM MICROGRAMHCL HYDROCHLORIDE UL MICROLITERL LITER UMOLAR MICROMOLARMCI MILLICURIEII - 4
DRUG ProDUCT EKAMPLESSingle IngredientActive Ingredient.. MEPERIDINE HYDROCHLORIDEDosage Form; Route <strong>of</strong> Administratioo• INJECTABLE; INJECTIONDEHEROL. N AP WINTHROP VSTER LING 2SMG/ML '" SOHG/ML '" 7SMG/ML '"T ra de or G ener IC ames AP lOOMG/MLL...-________ ....: HEPERIDZHE HCLTherapeutic 19quivalence (TE)Af ELKINS-SINN/AHROBINS 2SMGIML '" SOHG/ML '" 7SMG/ML '"100MG/M1,Code for Multisource Prodoct• AP. INT'L MEDICATION SYS lOMGIMLAP KNOLL PHARM2SMG/ML '" 50MS/ML '" 7SMG/ML '"Af100HG/MLAP PARKE-DAVIS/W-L SOMG/ML '" 7SMG/ML '" 100MG/HLSingle Source Product (NO TE Code) ___ AP VITARINE/wEST CHEM SOMG/ML '" 100MG/ML~AP WYETH LABS/ANtiO 2SMG/ML '" SOMG/ML '" 7SMG/ML '"AP100MG/MLL..-_______ ~. DEMEROLSYRUP; ORALAWlicatioo Holder • WINTHROP VSTERLING 50MG/5MLAsterisks Separate Available Strengths <strong>of</strong> a Product--------------------------------------~AlphabeticallyFirst Active IngredientMultiple Ingredientswi th Product Informatioo--------------------------------~.~ EPIHEPHRIN~ LIDOCAINE HYDROCHLORIDEProdlct Informatioo • ~1MINJECTABLE; INJECTIONALPHACAZHE HeL W/ EPZHEPHRIHECARLISLE LABS 10 UGM/ML;2? * 20 UGMIML;2?With Cross-ReferenceAlphabeticallySecond Active Ingredient • LIDOCAINE HYDROCHLQRIDE; *I1ULTIPLE*SEE DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDECross-Reference toSEE DEXTROSE; LIDOCAINE HYDROCHLORIDEProduct Informatim• SEE EPINEPHRINE i LIDOCAINE HYDROCHLORIDE
Page 5: RXD AND DRUG ACMINISTRATIONAPProVED
Page 9: approved application, a list of app
Page 12 and 13: products that have been approved" i
Page 14 and 15: To assist the user in relating the
Page 16 and 17: an evaluatien of therapeutic equiva
Page 18 and 19: ioavailability data is required for
Page 20 and 21: B - Drug products that FDA does not
Page 22 and 23: and the rate of absorption.pharmace
Page 24 and 25: 4. Erythromycin stearate Tablets -
Page 27 and 28: II. LISTINGSA. FORMAT GUIDEThis p..
Page 29: CURRENT STATUS - POSSIBLY EFFECTIVE
Page 33 and 34: APPROVED PRESCRIPTION DRUG PRODUCTS
Page 55 and 56: j./APPROVED PRESCRIPTION DRUG PRODU
Page 65 and 66: -,----APPROVED PRESCRIPTION DRUG PR
Page 67 and 68: APPROVED PRESCRI~TIOHDRUG PRODUCTSD
Page 77 and 78: DIMENHYDlHNATEAPPROVED PRESCRIPTION
Page 81 and 82:
------"".,APPROVED PRESCRIPTION DRU
Page 83 and 84:
APPROVED PRESCRIPTION DRUG PRODUCTS
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
APPROVED ¥RESCRIPTION DRUG PRODUCT
Page 93 and 94:
Page 95 and 96:
'''"APPROVED PRESCRIPTION DRUG PROD
Page 97 and 98:
----..//APPROVED PRESCRIPTION DRUG
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
"~''''''-- .APPROVED PRESCRIPTION D
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
PERCORTEN PIVALATE, DESOXYCORTICOST
Page 191 and 192:
Page 193 and 194:
Page 195:
oAPPROVED PRESCRIPTION DRUG PRODUCT
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
APPROVED PRESCRIPTIOH DRUG PRODUCTS
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243:
Page 246 and 247:
PRESCRIPTION DRUG PRODUCTS DEEMED A
Page 248 and 249:
Page 250 and 251:
show all

first edition (1980) of the Orange Book - FDA Law Blog

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?